UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $562

Benzinga · 10/17 15:53
UBS analyst Colin Bristow maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $477 to $562.